Pr ecis: Findings establish that STAT3 is essential to maintain the pathophysiology of an aggressive form of B cell lymphoma and they offer a preclinical proof of concept for STAT3 inhibition as a therapeutic approach to treat this cancer.
Pr ecis: A third generation drug can overcome an acquired mutation in BCR-ABL that confers resistance to all currently approved targeted therapies for CML, addressing a critical unmet need to control drug resistance in this disease.
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Several recent studies have demonstrated the involvement of cell-surface nucleolin in angiogenesis and tumor growth. In this study, we addressed the following questions: Does N6L (or Nucant), a synthetic ligand of cell-surface nucleolin (nM range), block angiogenesis and tumor growth? What are its mechanisms of action, its bio-distribution and finally does it target other cell surface nucleolin partner proteins?
The key findings of this study are that: N6L inhibits anchorage-dependent and independent growth of several tumor cell lines and blocked angiogenesis N6L inhibit, in vivo tumor growth in a number of mouse subcutaneous human xenograft models N6L bio-distribution studies indicate that N6L rapidly localizes selectively in tumor tissue (see cover figure) N6L is a pro-apoptotic molecule, as demonstrated by in vivo as well as in vitro experiments Pull-down experiments and mass-spectrometry analysis have confirmed that nucleophosmin is a partner for nucleolin and also a target (nM range) for N6L
ImmuPharma group is currently developing N6L in Phase I/IIa clinical trials before initiating full efficacy studies in various indications as identified during this series of experiments. We believe that these findings pave the way for a novel approach of cancer treatment. For details, see the article by Destouches and colleagues on page 3296 of this issue.
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